Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US president orders review of all pre-emption rules issued in last ten years

This article was originally published in RAJ Devices

Executive Summary

US president Barack Obama wants a review of all federal regulations issued in the last ten years that intend to pre-empt individual state laws, to ascertain whether these were issued with sufficient legal basis1. The review could have major implications for the medical technology industry, which has long favoured “uniform regulations” to increase the certainty of the regulatory process and to avoid facing product liability suits under state laws2.

You may also be interested in...



EU Checks Pharma’s Appetite To Share Market Launch Intentions

A new EU pilot will help drug regulators and policymakers understand the factors influencing the uneven availability of centrally authorized medicines in the member states.

Scathing Report On UK Health Care System Failings Calls For Big Changes

A damning UK report makes uncomfortable reading about how thousands of women suffered avoidable harm from the anti-epileptic drug sodium valproate and two other medical interventions and how safety concerns raised were dismissed, overlooked and ignored.

Global Pharma Guidance Tracker – June 2020

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

UsernamePublicRestriction

Register

LL1128165

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel